EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Dynamic circulating biomarkers for predicting adverse events in PRaG therapy: a pooled analysis and model construction from PRaG series clinical trials

Wei-Wu Chen, Shi-Cheng Li, Qian Yin, Mei-Ling Xu, Jun-Jun Zhang, Xiang-Rong Zhao, Peng-Fei Xing, Yue-Hong Kong, Li-Yuan Zhang

Cancer Immunology, Immunotherapy · 27.01.2026 · 75 (2)

DOI: 10.1007/s00262-025-04292-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 27.01.2026. Verfasst von Wei-Wu Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: PRaG Center, Center for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University, Suzhou, China. Hauptthemen laut MEDLINE: Neoplasms, Biomarkers, Tumor, Granulocyte-Macrophage Colony-Stimulating Factor, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: PRaG therapy (PD-1/PD-L1 inhibitor combined with Radiotherapy and Granulocyte-macrophage colony-stimulating factor) has emerged as a novel, intensive, and promising combined regimen for advanced solid tumors. It has been adopted as a National Health Commission-promoted technology in China, demonstrating significant survival benefits. This study aims to delineate the adverse events (AEs) profile of PRaG therapy and evaluate the predictive value of dynamic circulating biomarkers for moderate-to-severe AEs. METHODS: 203 patients with advanced solid tumors initiating PRaG therapy were prospectively enrolled and stratified by maximum treatment-related AEs severity (AE ≤ Grade1 vs. AE ≥ Grade2). The predictive value was assessed by comparing circulating indicators at baseline and one cycle prior to AEs onset (pre-AEs cycle). A predictive model was then constructed and subjected to independent internal validation. RESULTS: Patients experiencing AE ≥ Grade2 exhibited significantly superior survival outcomes. Multivariate analysis of dynamic circulating indicators revealed that pre-AEs cycle levels of Interleukin-2 (IL-2, p = 0.004), CD4 + effector memory T cells (p = 0.001), CD8 + effector memory T cells (p = 0.012), and the CD4 + effector/CD8 + effector memory T-cell ratio (p < 0.001) were independent predictors for AE ≥ Grade2. Integrating these fine typing of circulating T lymphocyte subsets into the prediction model significantly enhanced performance (AUC increased from 0.685 to 0.867), with independent internal validation confirming model reliability (AUC = 0.913). CONCLUSION: This study successfully delineated the real-world safety profile of PRaG therapy and identified a distinct set of dynamic circulating biomarkers strongly associated with moderate-to-severe AEs. The established non-invasive prediction model offers an effective tool for clinical early warning and proactive management in PRaG patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsBiomarkers, TumorGranulocyte-Macrophage Colony-Stimulating FactorAntineoplastic Combined Chemotherapy ProtocolsDrug-Related Side Effects and Adverse ReactionsImmune Checkpoint InhibitorsHumansFemaleMaleMiddle AgedAgedAdultPrognosisBiomarkersProspective Studies

Stichwörter der Autor:innen

Adverse eventsCirculating biomarkersDynamic predictionPRaG therapy

Substanzen

Biomarkers, TumorGranulocyte-Macrophage Colony-Stimulating FactorBiomarkersImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • PRaG Center, Center for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University, Suzhou, China.
  • PRaG Center, Center for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University, Suzhou, China. kkyuehong@163.com.
  • PRaG Center, Center for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University, Suzhou, China. zhangliyuan@suda.edu.cn.

Förderung

  • The National Natural Science Foundation of China

Zitieren

APA

Chen, W. W., Li, S. C., Yin, Q., Xu, M. L., Zhang, J. J., Zhao, X. R., Xing, P. F., Kong, Y. H., & Zhang, L. Y. (2026). Dynamic circulating biomarkers for predicting adverse events in PRaG therapy: a pooled analysis and model construction from PRaG series clinical trials. Cancer Immunology, Immunotherapy, 75(2). https://doi.org/10.1007/s00262-025-04292-w

Vancouver

Chen WW, Li SC, Yin Q, Xu ML, Zhang JJ, Zhao XR, et al. Dynamic circulating biomarkers for predicting adverse events in PRaG therapy: a pooled analysis and model construction from PRaG series clinical trials. Cancer Immunology, Immunotherapy. 2026;75(2). doi:10.1007/s00262-025-04292-w

BibTeX
@article{Chen2026,
  author = {Chen, Wei-Wu and Li, Shi-Cheng and Yin, Qian and Xu, Mei-Ling and Zhang, Jun-Jun and Zhao, Xiang-Rong and Xing, Peng-Fei and Kong, Yue-Hong and Zhang, Li-Yuan},
  title = {Dynamic circulating biomarkers for predicting adverse events in PRaG therapy: a pooled analysis and model construction from PRaG series clinical trials},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  volume = {75},
  number = {2},
  doi = {10.1007/s00262-025-04292-w}
}
Kostenlos starten →